

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Asghar Najjam</u>			2. Date of Event Requiring Statement (Month/Day/Year) <u>08/18/2020</u>		3. Issuer Name and Ticker or Trading Symbol <u>Sorrento Therapeutics, Inc. [SRNE]</u>		
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ <u>Chief Financial Officer</u>			5. If Amendment, Date of Original Filed (Month/Day/Year)	
C/O SORRENTO THERAPEUTICS, INC. 4955 DIRECTORS PLACE						6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	
(Street) <u>SAN DIEGO CA 92121</u>							
(City) (State) (Zip)							

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Options	(1)	11/29/2029	Common Stock	50,000	2.92	D	
Stock Options	(2)	12/06/2029	Common Stock	50,000	3.52	D	
Stock Options	(3)	06/15/2030	Common Stock	80,000	4.89	D	

Explanation of Responses:

- 1/4th of the original number of shares subject to the option shall vest on November 29, 2020, and 1/48th of the original number of shares subject to the option shall vest on a monthly basis thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
- 1/4th of the original number of shares subject to the option shall vest on December 6, 2020, and 1/48th of the original number of shares subject to the option shall vest on a monthly basis thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
- 1/4th of the original number of shares subject to the option shall vest on June 15, 2021, and 1/48th of the original number of shares subject to the option shall vest on a monthly basis thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date.

Remarks:

Exhibit 24 - Power of Attorney

/s/Najjam Asghar

** Signature of Reporting Person

08/21/2020

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Exhibit 24
POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Henry Ji, Ph.D. and Brian Sun, signing singly, the undersigned to

- (1) execute for and on behalf of the undersigned, an officer, director and/or holder of 10% or more of a registered class of securities of Sorbus Therapeutics, Inc.
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Financial Instruments
- (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of any such attorney-in-fact, may be necessary or desirable to complete and execute any such Financial Instruments

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever that may be necessary or desirable to complete and execute any such Financial Instruments.

This Power of Attorney shall remain in full force and effect with respect to the undersigned until the earliest to occur of (a) such date that the undersigned shall so direct in writing, or (b) the death of the undersigned.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 18th day of August, 2020.

/s/ Najjam Asghar
Signature

Najjam Asghar
Print Name